Development asset linked to Biocodex in public FDA and regional records.
pharma · Dravet syndrome · Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
Biocodex
Biocodex drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Gentilly, FR HQ
1953 Founded
1,648 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Gentilly, FR
- Founded
- 1953
- Employees
- 1,648
- Programs
- 5
- Drugs
- 15
- Patents
- 25
Biocodex pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Biocodex drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Biocodex in public FDA and regional records.
-
Development asset linked to Biocodex in public FDA and regional records.
-
Development asset linked to Biocodex in public FDA and regional records.
-
Development asset linked to Biocodex in public FDA and regional records.
-
dodecafluoropentane
Various (V08)Various (V08) compound in Biocodex's portfolio. Mechanism: Ultrasound contrast agent.
- Mechanism
- Ultrasound contrast agent
-
Development asset linked to Biocodex in public FDA and regional records.
-
Development asset linked to Biocodex in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Biocodex in public FDA and regional records.
-
Development asset linked to Biocodex in public FDA and regional records.
-
Development asset linked to Biocodex in public FDA and regional records.
-
US regulatory status: approved.
-
stiripentol
Nervous system (N03)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Biocodex in public FDA and regional records.
-
Development asset linked to Biocodex in public FDA and regional records.